Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2017-06, Vol.64 (11), p.1612-1614
Hauptverfasser:	Parker, Robert A., Rabideau, Dustin J., Sax, Paul E., Tierney, Camlin, Daar, Eric S., Collier, Ann C., Losina, Elena, Freedberg, Kenneth A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adhesion Adult AIDS Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use BRIEF REPORT Clinical trials Dideoxynucleosides - administration & dosage Dideoxynucleosides - therapeutic use Drug Combinations Drugs Female HIV Infections - drug therapy HIV-1 - drug effects Humans Intervention Lamivudine - administration & dosage Lamivudine - therapeutic use Male Medical research Medication Adherence Patient compliance Patients RNA, Viral - blood Self Report Tenofovir - administration & dosage Tenofovir - therapeutic use Treatment Failure Viral Load - drug effects Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/cix176